People · Operator
Named in public records as an officer, director or promoter · active 2018–2019 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gossamer Bio, Inc. | — | Biotechnology | Series D+ | $632.6M | $3.2B | 2018 |
| Aligos Therapeutics, Inc. | — | Biotechnology | Series D+ | $282.2M | $940.9M | 2019 |
| Beam Therapeutics Inc. | — | Pharmaceuticals | Series D+ | $218.6M | $4.8B | 2018 |
| NextCure, Inc. | — | Biotechnology | Series C | $129.9M | $113.9M | 2018 |
Michael Yi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Yi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 2 | 22 |
| Kristina Burow | 2 | 16 |
| Richard Lim | 1 | 14 |
| Jack Nielsen | 1 | 13 |
| Judith Li | 1 | 8 |
| Peter Hirth | 1 | 7 |
| Robert Nelson | 1 | 7 |
| David Kabakoff | 1 | 7 |
| Peter Moldt | 1 | 6 |
| STEPHEN KNIGHT | 1 | 6 |
| Faheem Hasnain | 1 | 5 |
| John Fry | 1 | 4 |
| John Evans | 1 | 4 |
| ASHER RUBIN | 1 | 3 |
| Lawrence Blatt | 1 | 3 |
| Carole Neuchterlein | 1 | 3 |
| Feng Zhang | 1 | 3 |
| Elaine V. Jones | 1 | 3 |
| Kathleen Glaub | 1 | 3 |
| MARK FISHMAN | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.